Natoli, J. L. et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 30, 599–609 (2010).

Article  CAS  PubMed  Google Scholar 

Stovner, L. J., Hagen, K., Linde, M. & Steiner, T. J. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J. Headache Pain 23, 34 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Olesen, J. Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia 38, 1–211 (2018).

Article  Google Scholar 

Bigal, M. E., Serrano, D., Reed, M. & Lipton, R. B. Chronic migraine in the population. Neurology 71, 559–566 (2008).

Article  PubMed  Google Scholar 

Dodick, D. W. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50, 921–936 (2010).

Article  PubMed  Google Scholar 

Aurora, S. K. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30, 793–803 (2010).

Article  CAS  PubMed  Google Scholar 

Diener, H. C. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30, 804–814 (2010).

Article  CAS  PubMed  Google Scholar 

Brin, M. F. et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord. 2, 237–254 (1987).

Article  CAS  PubMed  Google Scholar 

Foster, L., Clapp, L., Erickson, M. & Jabbari, B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56, 1290–1293 (2001).

Article  CAS  PubMed  Google Scholar 

Cheshire, W. P., A. S. M. J. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59, 65–69 (1994).

Article  PubMed  Google Scholar 

Freund, B., Schwartz, M. & Symington, J. M. Botulinum toxin: new treatment for temporomandibular disorders. Br. J. Oral Maxillofac. Surg. 38, 466–471 (2000).

Article  CAS  PubMed  Google Scholar 

Wissel, J. et al. Management of spasticity associated pain with botulinum toxin A. J. Pain Symptom Manag. 20, 44–49 (2000).

Article  CAS  Google Scholar 

Bach K, S. R. The multispecialty toxin: a literature review of botulinum toxin. Plast. Reconstr. Surg. Glob. Open 10, e4228 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Binder, W. J., Blitzer, A. & Brin, M. F. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol. Surg. 24, 1198–1205 (1998).

Article  CAS  PubMed  Google Scholar 

Binder, W. et al. Botulinum toxin type A (BTX-A) for migraine: an open label assessment. Mov. Disord. 13, abstr. P4-104 (1998).

Binder, W. J., Brin, M. F., Blitzer, A., Schoenrock, L. D. & Pogoda, J. M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123, 669–676 (2000).

Article  CAS  PubMed  Google Scholar 

Evers, S., Rahmann, A., Vollmer-Haase, J. & Husstedt, I. W. Treatment of headache with botulinum toxin A — a review according to evidence-based medicine criteria. Cephalalgia 22, 699–710 (2002).

Article  CAS  PubMed  Google Scholar 

Aurora, S. K., Gawel, M., Brandes, J. L., Pokta, S. & VanDenburgh, A. M. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47, 486–499 (2007).

Article  PubMed  Google Scholar 

Saper, J. R., Mathew, N. T., Loder, E. W., Degryse, R. & Vandenburgh, A. M. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med. 8, 478–485 (2007).

Article  PubMed  Google Scholar 

Relja, M. et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27, 492–503 (2007).

Article  CAS  PubMed  Google Scholar 

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05028569 (2024).

Silberstein, S. et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28, 484–495 (2008).

Article  CAS  PubMed  Google Scholar 

Tassorelli, C. et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38, 815–832 (2018).

Article  PubMed  Google Scholar 

Matharu, M. et al. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J. Headache Pain 18, 78 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Lipton, R. B. et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 36, 899–908 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Aurora, S. K. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51, 1358–1373 (2011).

Article  PubMed  Google Scholar 

Aurora, S. K. et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol. Scand. 129, 61–70 (2014).

Article  CAS  PubMed  Google Scholar 

Silberstein, S. D. et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J. Neurol. Neurosurg. Psychiatry 86, 996–1001 (2015).

Article  PubMed  Google Scholar 

Bendtsen, L. et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J. Headache Pain 19, 91 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Silberstein, S. D. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol. Sci. 331, 48–56 (2013).

Article  CAS  PubMed  Google Scholar 

Diener, H. C. et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur. J. Neurol. 21, 851–859 (2014).

Article  PubMed  Google Scholar 

Silberstein, S. D. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47, 170–180 (2007).

Article  PubMed  Google Scholar 

Brandes, J. L. MIGR-002 Study Group. et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291, 965–973 (2004).

Article  CAS  PubMed  Google Scholar 

Rothrock, J. F. et al. FORWARD Study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59, 1700–1713 (2019).

Article  PubMed  PubMed Central